Industry Strength Score
32/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ERYTECH PHARMA - SPON ADR (ERYP) Stock Price & Overview
NASDAQ:ERYP • US29604W1080
Current stock price
0.78 USD
0 (0%)
Last:
The current stock price of ERYP is 0.78 USD. Today ERYP is down by 0%. In the past month the price decreased by -9.52%. In the past year, price decreased by -30.36%.
ERYP Key Statistics
52-Week Range0.3 - 1.472
Current ERYP stock price positioned within its 52-week range.
1-Month Range0.711 - 0.9599
Current ERYP stock price positioned within its 1-month range.
- Market Cap
- 26.612M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.55
- Dividend Yield
- N/A
ERYP Stock Performance
Today
0%
1 Week
-10.86%
1 Month
-9.52%
3 Months
-20.41%
Longer-term
6 Months +136.29%
1 Year -30.36%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
ERYP Stock Chart
ERYP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ERYP. When comparing the yearly performance of all stocks, ERYP is a bad performer in the overall market: 86.71% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ERYP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ERYP. ERYP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ERYP Earnings
Next Earnings DateSep 11, 2023
Last Earnings DateMay 9, 2023
PeriodQ4 / 2022
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise 697.48%
ERYP Forecast & Estimates
9 analysts have analysed ERYP and the average price target is 3.94 USD. This implies a price increase of 405.11% is expected in the next year compared to the current price of 0.78.
For the next year, analysts expect an EPS growth of 22.35% and a revenue growth 16.44% for ERYP
Analysts
Analysts42.22
Price Target3.94 (405.13%)
EPS Next Y22.35%
Revenue Next Year16.44%
ERYP Financial Highlights
Over the last trailing twelve months ERYP reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS increased by 99.68% compared to the year before.
Income Statements
Revenue(TTM)7.66M
Net Income(TTM)-17.28M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.44 |
Chartmill High Growth Momentum
EPS Q2Q%102.44%
Sales Q2Q%198.12%
EPS 1Y (TTM)99.68%
Revenue 1Y (TTM)59.04%
ERYP Ownership
Ownership
Inst Owners0.04%
Shares34.12M
Float32.52M
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
ERYP Industry Overview
ERYP operates in the Biotechnology sub-industry within the Health Care sector. This group contains 51 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
77/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
16%
Outperformed 16% of sub-industries
3 Month Rank
19%
Outperformed 19% of sub-industries
6 Month Rank
36%
Outperformed 36% of sub-industries
Industry Fundamentals & Breadth
- Members
- 51
- New Highs
- 2%
- New Lows
- 11.8%
- Average ROE
- 26.9%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 26.1%
- Average P/E
- 38.5
- Average Fwd P/E
- 30.5
- Average Debt/Equity
- 0.0
ERYP Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.59 | 365.426B | ||
| AMGN | AMGEN INC | 13.88 | 178.001B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 163.407B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.77 | 107.828B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 74.154B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 27.54 | 39.51B | ||
| NTRA | NATERA INC | N/A | 29.378B | ||
| INSM | INSMED INC | N/A | 28.764B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.641B | ||
| BIIB | BIOGEN INC | 11.44 | 27.453B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.52 | 25.001B | ||
| INCY | INCYTE CORP | 10.61 | 19.286B | ||
| MRNA | MODERNA INC | N/A | 17.993B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ERYP
Company Profile
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
Company Info
IPO: 2013-05-07
ERYTECH PHARMA - SPON ADR
60 avenue Rockefeller, Batiment Adenine
Lyon AUVERGNE-RHONE-ALPES 69008 FR
CEO: Gil Beyen
Employees: 49
Phone: 33478744438.0
ERYTECH PHARMA - SPON ADR / ERYP FAQ
What does ERYTECH PHARMA - SPON ADR do?
ERYTech Pharma SA is a biopharmaceutical company, which develops medical products. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. The firm offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The firm's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.
What is the current price of ERYP stock?
The current stock price of ERYP is 0.78 USD.
Does ERYP stock pay dividends?
ERYP does not pay a dividend.
What is the ChartMill rating of ERYTECH PHARMA - SPON ADR stock?
ERYP has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the number of employees for ERYTECH PHARMA - SPON ADR?
ERYTECH PHARMA - SPON ADR (ERYP) currently has 49 employees.
What is the next earnings date for ERYP stock?
ERYTECH PHARMA - SPON ADR (ERYP) will report earnings on 2023-09-11, after the market close.
Can you provide the ownership details for ERYP stock?
You can find the ownership structure of ERYTECH PHARMA - SPON ADR (ERYP) on the Ownership tab.